全文获取类型
收费全文 | 26293篇 |
免费 | 2754篇 |
国内免费 | 46篇 |
专业分类
耳鼻咽喉 | 325篇 |
儿科学 | 787篇 |
妇产科学 | 509篇 |
基础医学 | 3488篇 |
口腔科学 | 537篇 |
临床医学 | 3122篇 |
内科学 | 4512篇 |
皮肤病学 | 251篇 |
神经病学 | 2845篇 |
特种医学 | 1008篇 |
外科学 | 4186篇 |
综合类 | 664篇 |
一般理论 | 5篇 |
预防医学 | 2885篇 |
眼科学 | 521篇 |
药学 | 1658篇 |
中国医学 | 11篇 |
肿瘤学 | 1779篇 |
出版年
2021年 | 276篇 |
2020年 | 210篇 |
2019年 | 390篇 |
2018年 | 490篇 |
2017年 | 339篇 |
2016年 | 340篇 |
2015年 | 411篇 |
2014年 | 569篇 |
2013年 | 947篇 |
2012年 | 1317篇 |
2011年 | 1271篇 |
2010年 | 689篇 |
2009年 | 683篇 |
2008年 | 1188篇 |
2007年 | 1166篇 |
2006年 | 1137篇 |
2005年 | 1051篇 |
2004年 | 1097篇 |
2003年 | 1031篇 |
2002年 | 891篇 |
2001年 | 887篇 |
2000年 | 915篇 |
1999年 | 727篇 |
1998年 | 300篇 |
1997年 | 252篇 |
1996年 | 278篇 |
1995年 | 281篇 |
1994年 | 255篇 |
1993年 | 280篇 |
1992年 | 633篇 |
1991年 | 618篇 |
1990年 | 592篇 |
1989年 | 602篇 |
1988年 | 562篇 |
1987年 | 588篇 |
1986年 | 525篇 |
1985年 | 538篇 |
1984年 | 395篇 |
1983年 | 354篇 |
1982年 | 241篇 |
1981年 | 203篇 |
1980年 | 200篇 |
1979年 | 362篇 |
1978年 | 202篇 |
1977年 | 200篇 |
1976年 | 225篇 |
1975年 | 183篇 |
1974年 | 239篇 |
1973年 | 226篇 |
1972年 | 186篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Lee Terry Thompson Atalie C. Wisely C. Ellis Nash Mitchell G. Postel Eric A. Herndon Leon 《Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie》2022,260(3):949-956
Graefe's Archive for Clinical and Experimental Ophthalmology - To investigate comorbidities and medications associated with acute (ASCH) and delayed (DSCH) suprachoroidal hemorrhage (SCH), and... 相似文献
2.
3.
4.
McAllister Milly J. Kirkwood Kathryn Chuah Shaun C. Thompson Emily J. Cartwright Jennifer A. Russell Clark D. Dorward David A. Lucas Christopher D. Ho Gwo-tzer 《Inflammation》2022,45(2):567-572
Inflammation - The coronavirus SARS-CoV-2 contributes to morbidity and mortality mainly as a result of immune-pathology in the lungs. Recent data has shown multi-system involvement with widespread... 相似文献
5.
6.
Koji Sasaki Hagop Kantarjian Guillaume Richard-Carpentier Nicholas Short Farhad Ravandi Maria Khouri Guillermo Garcia-Manero Naval Daver Tapan Kadia Marina Konopleva Nitin Jain Ghayas Issa Jovitta Jacob Rebecca Garris Musa Yilmaz Philip Thompson Patrice Nasnas Naveen Pemmaraju Elias Jabbour 《Clinical Lymphoma, Myeloma & Leukemia》2019
7.
8.
Oliver A. Cornely Martin Hoenigl Cornelia Lass‐Flrl Sharon C. ‐A. Chen Dimitrios P. Kontoyiannis C. Orla Morrissey George R. Thompson 《Mycoses》2019,62(9):716-729
Breakthrough invasive fungal infections (IFIs) have emerged as a significant problem in patients receiving systemic antifungals; however, consensus criteria for defining breakthrough IFI are missing. This position paper establishes broadly applicable definitions of breakthrough IFI for clinical research. Representatives of the Mycoses Study Group Education and Research Consortium (MSG‐ERC) and the European Confederation of Medical Mycology (ECMM) reviewed the relevant English literature for definitions applied and published through 2018. A draft proposal for definitions was developed and circulated to all members of the two organisations for comment and suggestions. The authors addressed comments received and circulated the updated document for approval. Breakthrough IFI was defined as any IFI occurring during exposure to an antifungal drug, including fungi outside the spectrum of activity of an antifungal. The time of breakthrough IFI was defined as the first attributable clinical sign or symptom, mycological finding or radiological feature. The period defining breakthrough IFI depends on pharmacokinetic properties and extends at least until one dosing interval after drug discontinuation. Persistent IFI describes IFI that is unchanged/stable since treatment initiation with ongoing need for antifungal therapy. It is distinct from refractory IFI, defined as progression of disease and therefore similar to non‐response to treatment. Relapsed IFI occurs after treatment and is caused by the same pathogen at the same site, although dissemination can occur. These proposed definitions are intended to support the design of future clinical trials and epidemiological research in clinical mycology, with the ultimate goal of increasing the comparability of clinical trial results. 相似文献
9.
10.
Kiran Naqvi MD Elias Jabbour MD Jeffrey Skinner BS MHA Kristin Anderson BS Sara Dellasala BS Musa Yilmaz MD Alessandra Ferrajoli MD Prithviraj Bose MD Philip Thompson MBBS Yesid Alvarado MD Nitin Jain MBBS Koichi Takahashi MD Jan Burger MD Zeev Estrov MD Gautam Borthakur MBBS Naveen Pemmaraju MD Shilpa Paul Pharm D Jorge Cortes MD Hagop M. Kantarjian MD 《Cancer》2020,126(1):67-75